Education
About Us
Working with TipRanks
Follow Us
Integrum AB Class B (SE:INTEG.B)
:INTEG.B
Top Page
Integrum AB Class B
(Frankfurt:INTEG.B)
Rating:53Neutral
Price Target:
kr22.00
▲(8.91%Upside)
Integrum AB Class B (INTEG.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr430.95M
Dividend YieldN/A
Average Volume (3M)39.46K
Price to Earnings (P/E)―
Beta (1Y)0.06
Revenue Growth-12.50%
EPS Growth-783.92%
CountrySE
Employees36
SectorHealthcare
Sector Strength41
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.44
Shares Outstanding20,694,328
10 Day Avg. Volume63,192
30 Day Avg. Volume39,460
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-5.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Integrum AB Class B Business Overview & Revenue Model
Company DescriptionIntegrum AB Class B (INTEG.B) is a Swedish company specializing in developing and marketing innovative solutions for orthopedic and reconstructive surgery, focused primarily on osseointegration technology. The company is renowned for its OPRA (Osseointegrated Prostheses for the Rehabilitation of Amputees) Implant System, which is designed to improve the quality of life for amputees by providing a direct connection between the prosthesis and the bone, enhancing mobility and comfort.
How the Company Makes MoneyIntegrum AB generates revenue primarily through the sale of its OPRA Implant System and related services. The company earns money by selling these advanced prosthetic solutions to healthcare providers and directly to patients globally. Additionally, Integrum engages in partnerships with medical institutions for research and development, which may also contribute to its revenue. The company leverages its expertise in osseointegration technology to expand its market presence and drive sales growth in the orthopedic and reconstructive surgery sectors.
Integrum AB Class B Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 90.01M | 104.12M | 74.27M | 55.72M | 43.09M | 26.75M | Gross Profit |
| 54.83M | 91.26M | 60.84M | 46.56M | 34.89M | 21.37M | EBIT |
| -32.49M | 6.51M | -19.70M | 1.04M | -1.85M | -15.68M | EBITDA |
| -22.34M | 8.76M | -20.24M | 2.60M | -1.59M | -14.98M | Net Income Common Stockholders |
| -19.55M | 4.03M | -16.18M | 21.27M | -2.14M | -15.69M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 14.65M | 16.90M | 41.92M | 75.34M | 7.66M | 13.06M | Total Assets |
| 180.29M | 164.86M | 165.17M | 180.44M | 37.21M | 32.20M | Total Debt |
| 5.25M | 6.42M | 7.92M | 580.89K | 485.92K | 723.80K | Net Debt |
| -9.40M | -10.48M | -34.01M | -74.76M | -7.17M | -12.34M | Total Liabilities |
| 17.69M | 22.07M | 21.64M | 20.70M | 12.91M | 8.47M | Stockholders Equity |
| 162.60M | 142.79M | 143.53M | 159.74M | 24.29M | 23.73M |
| Cash Flow | Free Cash Flow | ||||
| -58.94M | -24.37M | -36.50M | -49.55M | -7.47M | -19.06M | Operating Cash Flow |
| -44.88M | -12.74M | -25.10M | -20.28M | -5.76M | -18.72M | Investing Cash Flow |
| -14.07M | -11.63M | -11.40M | -29.27M | -1.71M | -343.68K | Financing Cash Flow |
| 45.23M | -648.54K | 3.08M | 117.23M | 2.06M | 21.51M |
Integrum AB Class B Technical Analysis
Positive
20.20
Price Trends
15.85
Positive
16.33
Positive
20.93
Negative
Market Momentum
1.25
Negative
64.89
Neutral
79.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:INTEG.B, the sentiment is Positive. The current price of 20.2 is above the 20-day moving average (MA) of 17.50, above the 50-day MA of 15.85, and below the 200-day MA of 20.93, indicating a neutral trend. The MACD of 1.25 indicates Negative momentum. The RSI at 64.89 is Neutral, neither overbought nor oversold. The STOCH value of 79.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:INTEG.B.
Integrum AB Class B Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
53 Neutral | kr430.95M | ― | -19.17% | ― | -12.50% | -783.92% | |
50 Neutral | kr395.29M | ― | -33.54% | ― | 72.05% | 33.68% | |
49 Neutral | kr531.83M | ― | -17.16% | ― | 17.75% | 18.05% | |
47 Neutral | €594.56M | ― | -48.55% | ― | -2.22% | -295.24% | |
46 Neutral | kr255.30M | ― | -88.97% | ― | -0.61% | 54.19% | |
43 Neutral | kr311.20M | ― | -159.24% | ― | -22.50% | 76.74% |
* Healthcare Sector Average
Performance Comparison
SE:INTEG.B
Integrum AB Class B
20.05
-38.75
-65.90%
SE:ACARIX
Acarix AB
0.24
-0.07
-22.37%
SE:DOXA
Doxa AB
0.46
-0.82
-64.19%
SE:MNTC
Mentice AB
21.20
-5.80
-21.48%
SE:QLINEA
Q-linea AB
0.05
-0.34
-88.37%
SE:BRAIN
BrainCool AB
1.60
-0.90
-35.87%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.